Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia
Clinical trial NCT02477670 · COMPLETED
Trial details
- NCT number
- NCT02477670
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-09-01
- Primary completion
- 2017-07-21
- Enrollment
- 145
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.